Well before 2020, Ohio State has already exceeded the university’s five-year goals for increased student financial aid and new resources generated through innovative partnerships. In addition, the university is on pace to surpass its efficiency goal by fiscal 2020.
Operational excellence and resource stewardship is a key element of the university’s Time and Change strategic plan.
A state performance audit released today recommends next steps in Ohio State’s ongoing work to reduce administrative costs.
The university volunteered for the performance audit as part of its commitment to operational excellence and resource stewardship, a pillar of Ohio State’s strategic plan. In work prior to the performance audit, Ohio State has used efficiency savings and innovative partnerships to fund more than $100 million in new need-based aid for Ohio students.
After a record-setting year for technology commercialization at Ohio State, fiscal 2019 has started with exciting news for another startup connected to university research.
A global biotechnology company announced today that it is buying Celenex and 10 associated gene-therapy programs for rare disorders for $100 million. Celenex is based on research by Ohio State professor Arthur Burghes and two colleagues at Nationwide Children’s hospital, Drs. Brian Kaspar and Kathrin Meyer.
Through Ohio State’s equity stake in the company, the university expects to net $1.4 million from the transaction. Amicus Therapeutics is the buyer.
Innovative funding Ohio State has extended our relationship with Coca-Cola for another 15 years through a pouring rights contract that supports student initiatives and strategic priorities.
The new pouring rights contract, which has a total projected value of $84.7 million, includes:
$2.25 million for student scholarships $1.88 million for student discovery projects and other educational initiatives Six student internships per year
Ohio State has a 20-year history with Cola-Cola. Through this renewed relationship, Coca-Cola will continue to offer a variety of beverages to the Columbus campus, drawing on its portfolio of more than 800 products, including 250...
Ohio State set a record high in licensing income from technology commercialization and expanded its startup porfolio new highs in fiscal 2018, demonstrating continuing momentum in the Corporate Engagement Office.
“The past year was a banner year for the development of Ohio State research,” said Michael Papadakis, interim senior vice president for Business and Finance and chief financial officer.
The university is launching a new travel initiative that will have short- and long-term benefits, Executive Vice President Provost Bruce A. McPheron and Senior Vice President and CFO Michael Papadakis announced today.
Starting Aug. 1, individuals traveling on university business must book their flights and car rentals through Ohio State’s travel partners. People may continue to directly arrange local flights within countries where booking through outside travel agencies is impractical.
The Board of Trustees today approved the fiscal year 2019 budget, which projects revenues will grow 4.7 percent to $7.5 billion for the entire university, including the Wexner Medical Center and all campuses. Spending is projected to be $6.9 billion.
The budget reflects the university’s fiscal strength and priorities including access and affordability, academic excellence and health care.
Technology Commercialization Ohio State startup AveXis Inc. is being acquired by one of the largest pharmaceutical companies in the world for $8.7 billion.
The company develops gene therapies using research that originated at Nationwide Children’s Hospital and Ohio State. AveXis announced the acquisition agreement with Novartis on Monday . The university could realize about $2.7 million from its stake in AveXis based on current and recently sold holdings.
AveXis is focused on treatments for rare and life-threatening neurological diseases, including a form of spinal muscular atrophy that is the leading genetic cause of infant mortality. Completion...